BPC-157 eye research: what corneal and retinal animal studies examined
Prepared by: Research Desk
Prepared by: Research Desk. Sources are linked for verification.
Status: Not approved. BPC-157 is not FDA-approved for any use, including any eye condition. It is prohibited at all times under the WADA anti-doping code. See our legal status file.
Searches for "BPC-157 eye research" usually lead to forum posts that present a handful of animal experiments as settled science. This explainer covers the published ophthalmic experiments: what models were used, what the researchers measured and reported, who ran them, and what that work cannot tell anyone about human eyes. It does not cover use, preparation or amounts. None of that is supported by the record, and this site does not publish it.
Where the eye research comes from
BPC-157 is a synthetic 15-amino-acid peptide. Its research history begins with gastric juice and stomach-protection experiments. The same Zagreb-based group that described it has published most of the later work across organ systems, including the gastrointestinal tract [3] and skin and other wound models [2]. Our history of the BPC-157 research traces that path.
The eye work follows the same pattern. The main summary is a 2023 review in Pharmaceuticals, written by members of that group. Its title presents BPC-157 as a "possible novel therapy" of glaucoma and other ocular conditions [1]. That framing matters. The review collects the group's own animal experiments and argues for their relevance. It is not an independent appraisal or a meta-analysis, and it reports no human data.
The models: what was done to the animals
The review describes several kinds of rat model [1]. Each one induces a specific injury or condition, then compares animals given BPC-157 with control animals.
Corneal epithelial defect and ulcer models
The cornea is the clear front surface of the eye. In these models, researchers removed or damaged its outer cell layer, or produced a corneal ulcer. They then tracked how fast the defect closed and whether the cornea stayed transparent. Defect closure is usually measured by staining the surface with a dye and photographing it over time. The review reports faster closure and preserved transparency in rats given BPC-157 compared with controls [1].
Dry-eye models
Dry eye was produced in rats, for example by removing the lacrimal (tear) gland. Researchers then assessed tear production and the state of the corneal surface. The review describes the BPC-157 groups as differing from controls on these measures [1].
Glaucoma, retinal and optic nerve models
The more complex models induced raised pressure inside the eye or cut off retinal blood flow. One method cauterizes veins on the eye's surface to raise intraocular pressure. Others ligate (tie off) vessels to produce retinal ischemia. Outcomes included pressure readings, retinal and optic nerve histology (tissue examined under a microscope) and blood vessel appearance. The review reports that BPC-157 groups differed from controls on these outcomes and links the results to the group's broader hypotheses about blood vessels and nitric oxide [1]. Our mechanism explainer covers those hypotheses.
What about rabbits?
Some secondary summaries mention rabbit corneal experiments. We could not verify the details of those papers against our source list, so we do not describe them here. If rabbit data exist, the same limits on animal evidence apply to them.
Sample sizes and study design
The review does not give a pooled count of animals. As far as its summary shows, the individual experiments used small groups of rats per condition, which is typical of this literature [1]. Anyone checking the record should go to each original paper. The questions to ask are how many animals were in each group, whether animals were randomly assigned, whether outcome assessors were blinded, and whether any animals were excluded and why. Our reader's checklist for BPC-157 studies sets out these questions in order.
Two structural features stand out:
Single-group origin. Almost all the ophthalmic papers come from one research group, which also originated the compound. Independent replication by unrelated labs is what normally separates a promising signal from a robust finding. For the eye models, it is largely missing.
Mostly positive results. Across many organ systems, this group's publications report consistently favourable outcomes [1][2][3]. A body of work with almost no reported null or negative results is a reason for caution, not confidence. Our overview of what rodent models can and cannot show discusses publication bias in more detail.
The angiogenesis question in the eye
The cornea is normally avascular, meaning it has no blood vessels, and that absence is part of why it is clear. Growth of new vessels into the cornea (neovascularization) is generally an unwanted change. The retina, by contrast, depends on tightly regulated blood supply, and abnormal vessel growth there is a feature of several serious eye diseases.
That makes angiogenesis (new blood vessel formation) a central safety question for any substance proposed for eye conditions. The originating group's 2025 commentary argues that BPC-157 acts on angiogenesis and nitric oxide in a balanced way. In its view, the compound counters damaging effects while maintaining protective functions [4]. That is a position paper responding to another review, not new controlled data. Whether any such balance holds in human ocular tissue has not been tested. Our evidence guide lists angiogenesis among the main open safety questions.
Why rat eye studies do not establish human safety or efficacy
Positive results in induced rat injuries do not show that a substance is safe or effective in people. The reasons are specific:
Anatomy differs. Rat eyes are far smaller, with different corneal thickness, tear film, blink rate and retinal structure. Drug penetration and clearance in the eye can differ substantially between species.
Induced injury is not human disease. A surgically created defect in a young, otherwise unaffected rat is not the same as chronic glaucoma, long-term dry eye or age-related retinal disease in humans.
Short follow-up. Animal experiments typically run for days or weeks. Many ocular safety concerns, such as vessel growth, pressure changes or lens effects, emerge over months or years.
No ocular toxicology data in humans. We found no published human study measuring how BPC-157 behaves in, or affects, the human eye.
Product identity is unverified. Laboratory material used in animal work is not the same as unregulated products sold online, whose purity and contents are often unknown.
The human record: nothing ophthalmic
The human evidence on BPC-157 in general is thin. A 2025 systematic review in orthopaedic sports medicine noted that the compound lacks FDA approval and that clinical evidence is very limited [5]. A 2026 systematic review of human evidence in orthopaedic and regenerative medicine likewise assessed a small number of low-quality reports [6]. The individual human reports include a small retrospective knee-pain series [7] and a pilot safety report on intravenous administration in a few volunteers [8]. None of these concerns the eye.
We are not aware of any published human ophthalmic clinical trial of BPC-157. There is no controlled study, no pilot and no case series in our verified sources. The eye evidence rests entirely on animal experiments.
Regulatory context
FDA lists BPC-157 among bulk drug substances nominated for compounding that may present significant safety risks [9]. FDA's Pharmacy Compounding Advisory Committee met on 23–24 July 2026 [10], and our legal status file covers that review in dated detail. WADA's Prohibited List bans the substance in sport at all times [11]. None of these records reflects any recognized ophthalmic use.
Further reading: evidence-appraisal books
Readers who want to judge animal and early-stage research on their own terms often find that a good methods book is the most durable tool. Useful criteria when comparing titles include whether the book covers animal-to-human translation, bias and blinding, and how to read a systematic review. It also helps to check whether the author explains statistics without heavy jargon and whether the edition is recent.
Price and format matter too. Many evidence-appraisal books come in paperback, e-book and audiobook editions, and older editions are often far cheaper while still covering core study-design principles.
A book focused on critical appraisal suits readers who mainly want to read papers sceptically. A broader research-methods text suits readers who want to understand how experiments are designed from scratch.
Look for titles with worked examples of real studies and clear chapters on publication bias and replication. These two topics matter most when a literature comes largely from one source.
Frequently asked questions
Has BPC-157 been tested in human eyes?
Not in any published study we could find. The ophthalmic record consists of animal experiments, mainly in rats, summarized in a 2023 review by the originating research group [1].
What eye conditions were modelled in animals?
The review describes rat models of corneal epithelial defects and ulcers, dry eye after tear-gland removal, raised intraocular pressure, and retinal ischemia from vessel ligation [1]. Each model induces an injury in otherwise unaffected animals.
Were the eye studies independently replicated?
Largely not. Nearly all the published ophthalmic work comes from one group, which also developed the compound. Independent replication is the main missing step.
Do animal eye results show BPC-157 is safe for eyes?
No. Species differences, short follow-up, induced rather than natural disease, and the unresolved angiogenesis question mean animal results cannot establish human ocular safety or efficacy [4].
Related on this site
BPC-157 animal studies: what rodent models can and cannot show
BPC-157 history: where the gastric peptide research came from
How to evaluate a BPC-157 study: a reader's checklist and reading list
For how pages on this site are sourced and how it is funded, see About BPC Recover.
Last updated: 23 October 2026.
Not medical advice. This page reports published research and regulatory records for information only.
Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.
Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.
Sources
Read next
How to evaluate a BPC-157 study: a reader's checklist and reading list
A five-question checklist for reading BPC-157 studies, applied to the three human reports and two systematic reviews, plus a labelled reading list on evidence appraisal.
Sports wearables buyer's guide: GPS watches, chest straps, trackers
How to compare wearables for athletes: what GPS watches, chest straps and activity trackers measure, which figures are estimates, and how to weigh battery, data export, privacy and price.
BPC-157 vs TB-500: the evidence and regulatory records compared
Two peptides, one thin record. How BPC-157 and TB-500 compare on human evidence, FDA's July 2026 compounding review and WADA's Prohibited List, with every unverified claim flagged.